产品名称
Anti-Dihydropyrimidine dehydrogenase/DPYD Antibody, from rabbit, purified by affinity chromatography
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human
species reactivity (predicted by homology)
bovine (based on 100% sequence homology), primate (based on 100% sequence homology), horse (based on 100% sequence homology), porcine (based on 100% sequence homology)
technique(s)
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... DPYD(1806)
Analysis Note
Evaluated by Western Blotting in human small intestine tissue lysate.
Western Blotting Analysis: 2.0 µg/mL of this antibody detected Dihydropyrimidine dehydrogenase/DPYD in 10 µg of human small intestine tissue lysate.
Western Blotting Analysis: 2.0 µg/mL of this antibody detected Dihydropyrimidine dehydrogenase/DPYD in 10 µg of human small intestine tissue lysate.
Application
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Apoptosis - Additional
This Anti-Dihydropyrimidine dehydrogenase/DPYD Antibody is validated for use in Western Blotting and Immunohistochemistry for the detection of Dihydropyrimidine dehydrogenase/DPYD.
Western Blotting Analysis: 2.0 µg/mL from a representative lot detected Dihydropyrimidine dehydrogenase/DPYD in 10 µg of human liver tissue lysate.
Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Dihydropyrimidine dehydrogenase/DPYD in human liver tissue.
Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Dihydropyrimidine dehydrogenase/DPYD in human liver tissue.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
DPYD is an important enzyme involved in pyrimidine base degradation and catabolism. DPYD catalyzes the reduction of uracil and thymine and also is a critical enzyme in the degradation of the chemotherapeutic drug 5-fluoruracil. DPYD is expressed in most cells and has highest activity in the liver and monocytes. Mutations in DPYD give rise to a range of symptoms and syndromes in patients ranging from no symptoms to highly convulsive and mental retardation caused by excessive amounts of uracil or thymine present in the blood. Because of its ability to degrade 5-fluorouracil, DPYD is studied as a cancer marker and a measure of therapeutic effects in many cancers. Recent research also shows that DPYD levels in the liver are regulated via microRNA interactions and an offer a new opportunity for modulation of this critical enzyme in health and disease.
~110 kDa observed. Uncharacterized band at ~47 kDa may be observed in some lysates.
Immunogen
Epitope: Near N-terminus
KLH-conjugated linear peptide corresponding to human Dihydropyrimidine dehydrogenase/DPYD near the N-terminus.
Other Notes
Concentration: Please refer to lot specific datasheet.
Physical form
Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Masaaki Murakawa et al.
Oncology letters, 14(2), 1505-1511 (2017-08-10)
The predictive roles of dihydropyrimidine dehydrogenase (DPD) in patients who undergo curative resection and adjuvant chemotherapy with S-1, which is the oral 5-fluorouracil prodrug tegafur combined with oteracil and gimeracil, remain unclear. In the present study, the clinical data from
Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population.
Eiji Hishinuma et al.
Frontiers in pharmacology, 13, 930470-930470 (2022-07-06)
Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is the rate-limiting enzyme in 5-fluorouracil (5-FU) degradation. In Caucasians, four DPYD risk variants are recognized to be responsible for interindividual variations in the development of 5-FU toxicity. However, these risk variants
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持